Joan Nickerson - 08 Jan 2025 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Administrative Officer
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Joan Nickerson
Issuer symbol
VERV
Transactions as of
08 Jan 2025
Net transactions value
$0
Form type
4
Filing time
10 Jan 2025, 09:00:05 UTC
Previous filing
03 Apr 2024
Next filing
03 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +225,000 $0.000000 225,000 08 Jan 2025 Common Stock 225,000 $6.01 Direct F1
transaction VERV Restricted Stock Units Award $0 +40,000 $0.000000 40,000 08 Jan 2025 Common Stock 40,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.